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Supplementary Figure 1: 
Mutation at codon 158 is a GOF p53 isoform (continue from Figure 1). 
(A) Lolliplots showing TCGA mutational profile of TP53 gene in lung squamous cell carcinoma (LUSC, top) and lung 
adenocarcinoma (LUAD, bottom). 
(B-H) Sanger sequencing of TP53 gene from cDNA of H2170 cells (B), Calu-1 wtp53 clone (C), and mutp53R158G clone 1 
(D), clone 2 (E), clone 3 (F), clone 7 (G) and clone 8 (H). 
(I) RT-qPCR quantification of MDM2 and CDKN1A mRNA expression in MRC5 and H2170 cell lines 48 hours after 
vehicle- or Nutlin-3a treatment. 
(J-M) RT-qPCR analyses of the basal mRNA levels of CDKN1A (J), MDM2 (K), PUMA (L) and PMAIP1 (Noxa) (M) in 
various p53 clones (p53-/-, p53wt, p53R158G). Data are expressed as average relative quantification ± SD (n = 3 independent 
experiments). 
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Supplementary Figure 2: 
High-content screening of anti-cancer compounds and epigenetic modulators on p53 clones (continue from Figure 2). 
(A-B) High-content screening of anti-cancer compounds and epigenetic modulators on isogenic p53 clones. The efficacy of 
the tested compounds was quantified relative to the mean viability of vehicle-treated cells (384-well format, in triplicates) (n 
= 1 independent experiment). Heatmap shows compounds filtered for specificity to p53-/- cells (A) or p53wt cells (B) (growth 
inhibition > 50% in specific cell type). 
(C) Validation of in vitro activity of selected compounds against p53 clones (p53-/-, p53wt, p53R158G) in dose-response (384-
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Synergistic cytotoxicity of cisplatin and belinostat in carcinoma cells with hotspot mutp53 status.
(A-B) Western blot measuring the changes in PARP and caspase-3 in lung cancer cells [H596 (G245C), ChaGo-k-1 
(C275F), H1417 (R175L), H1975 (R273H), Calu-1 (null), H520 (W146*), SK-MES-1 (E298*) and A549 (wt)] (A); breast 
cancer cells [BT-549 (R249S), HCC7 (R248Q), MDA-MB-468 (R273H) and SK-BR-3 (R175H)], and pancreatic cancer 
cells [MIA-Paca-2 (R248W) and PANC-1 (R273H)] (B) after 48 hours treatment with belinostat (PXD101; 0.1 μM) and 
cisplatin (CDDP; 3 or 10 μM). β-actin shown as loading control (n = 3 independent experiments).
(C-D) Densitometric quantification of pro/cleaved PARP (C) and pro/cleaved caspase 3 (D) respectively for blots in Figure 
3D. Relative fold change is normalized to β-actin, relative to single cisplatin treatment (1 µM). Data are represented as mean 
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Supplementary Figure 4
DNA binding and transactivation of mutp53 is required for induction of apoptosis.  
(A) Reporter assay measuring p53 promoter activity in H2170 cells after treatment with belinostat (PXD101; 0.1 μM) and 
cisplatin (CDDP; 3 μM) for 24, 48 and 72 hours. Data are represented as mean ± SD (n = 3 independent experiments). Two 
tailed Student’s t-test; *P < 0.05, **P < 0.01.
(B-C) Electrophoretic mobility shift assay (EMSA) was performed using proteins expressed with in vitro translation. WT 
and Arg158 p53 were expressed from their respective plasmids, and protein acetylation was performed using the HAT domain 
of p300/HAT and acetyl-CoA. Western blot detects the expressed and modified proteins (B). The expressed proteins were 
incubated with 50ng of DNA oligos, and separated on a 6% non-denaturing TBE gel. SYBR Green (left) and SYPRO Ruby 
(right) were used for detection of nucleic acid and protein respectively (n = 2 independent experiments).
(D) Western blot indicates changes in p53, PARP and caspase-3 in shRNA-mediated (shp53.1, shp53.2) (left) or siRNA-
mediated (scrambled and TP53 siRNA) (right) knockdown cells. 50 nM of siRNA was used per transfection. β-actin shown 
as loading control (n = 3 independent experiments). 
(E) Extent of apoptosis was quantified with Annexin V staining in vector control (shNT and shLuc) or p53 knockdown 
(shp53.1, shp53.2) stable cells. Data are represented as mean ± SD (n = 3 independent experiments). Two tailed Student’s t-
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Q1 95.17 95.99 98.45 96.72 96.30
Q2 2.17 1.42 0.44 1.36 1.98
Q3 1.84 2.27 0.92 1.31 1.09








Q1 71.51 79.28 88.78 83.42 74.22
Q2 23.80 17.13 9.56 10.86 22.03
Q3 0.67 1.17 0.86 2.40 1.18









Q1 22.79 22.52 22.92 22.94 27.45
Q2 2.55 0.58 1.14 0.80 3.19
Q3 34.69 38.51 54.36 42.84 35.53
















Q1 21.36 18.38 19.29 21.49 22.62
Q2 5.99 4.37 6.11 3.44 11.31
Q3 13.77 17.48 17.36 21.49 15.74












Supplementary Figure 5: 
Belinostat and cisplatin treatment differentially induce post-translational modifications of nuclear p53.
(A-B) High content analyses were performed for signal intensity of acetyl- (A) and p-p53 (B) in cell nucleus 
(immunofluorescence staining in Figure 4J). 8 fields were taken in each treatment group. Integrated density for each nucleus 
was determined by ImageJ. Data are represented as mean of each field± SD in a representative experiment (n = 3 
independent experiments).
(C) Scatter plots of individual nuclei for p53R158G are shown (X: log signal for acetyl-p53; Y: log signal for p-p53). Each 
scatter plot consists of > 400 nuclei. Gating was determined from vehicle control, upward shift indicates increase in 
phosphorylated p53, rightward shift indicates acetylated-p53. 
(D) Tabulation of percentage of cell distribution for each p53R158G clones is displayed (Q1: p-p53 negative, acetyl-p53 
negative; Q2: p-p53 negative, acetyl-p53 positive; Q3: p-p53 positive, acetyl-p53 negative; and Q4: p-p53 positive, acetyl-
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Supplementary Figure 6: 
Structural simulation predicts that acetylation of the lysine residues could enhance DNA binding of mutp53R158G
molecule.
(A) The panel show the crystal structure of the dimer of the DNA binding domain (DBD) of p53 bound to a fragment of 
DNA (PDB id 2AHI) with key residues shown. The gray colored cartoon depicts the DBD while the orange cartoon is the 
DNA backbone with sticks representing the nucelobases in A; the black sphere represents a Zinc ion which is required for 
stabilizing the DBD; the R158 sidechain is shown as grey sphere (carbon atoms) and blue spheres (nitrogen atoms); the 
Lysine residues are shown as gray sticks with the terminal nitrogen colored in blue while upon acetylation, the sidechain 
oxygen is shown as red; the other sidechains shown are colored as: carbon – grey, oxygen – red, nitrogen – blue;  the 
dimerization helix is shown as green.  
(B-D) The panels show the conformations taken from the Molecular Dynamics simulations of the DBD in its WT (B), 
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Comparative analyses of the genome-wide binding and transcriptomic regulations reveal differential expression 
patterns of wtp53 and p53R158G. 
(A) p53wt-binding loci identified by p53 ChIP-seq analysis on Calu-1 cells treated with vehicle or belinostat/cisplatin 
combination for 24 hours (n = 1). Meta-peak analysis showing distribution of p53wt-binding sites across 3,000 bp from the 
TSS of the nearest downstream gene (Left, top). Density heatmap of the wtp53-binding sites (±3,000 bp from TSS) 
examined by ChIP-seq (Right). Canonical wild-type p53 consensus motif was identified by MEME/TomTom from the TSS-
proximal ChIP-Seq peaks (bottom left).  
(B) KEGG enrichment (number of genes and statistics) of wtp53 and mutp53-induced genes upon drug treatment from 
AmpliSeq analysis. 
(C-H) Integrative Genomics Viewer display of mutp53 occupancy over promoter region of MDM2 (C), GADD45A (D), 
PMAIP1 (E), RAD51 (F), KAT6A (G), KMT2D (H) genes in vehicle- or drug-treated cells (p53wt, p53R158G). 
(I-L) RT-qPCR quantification of MDM2 (I), GADD45A (J), PMAIP1 (Noxa) (K), RAD51 (L) genes in Calu-1 (p53-/-, p53wt, 
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Supplementary Figure 8: 
Distinctive genome-wide binding patterns of p53R158G from that of wild-type p53. 
Heatmaps showing the enrichment of p53 ChIP-Seq peaks (± 3,500 bp from peak center) identified from p53wt or p53R158G





































































































































































Supplementary Figure 9: 
Comet tail analysis of DNA damage in wtp53 and p53R158G cells after exposure to belinostat and/or cisplatin.
(A) Comet assay measuring the extent of DNA damage 48 hours after treatment with belinostat (PXD101; 0.1 μM) and 
cisplatin (CDDP; 10 μM) in Calu-1 (p53-/-, p53wt, p53R158G) cells. Immunofluorescence images was visualized and captured 
to determine the amount of DNA damage present in individual nuclei. At least four independent fields were taken for each 
condition with a minimum of 100 nuclei per group (n = 3 independent experiments). Representative confocal images are 
shown at 20× magnification. Scale bar, 50 µm.
(B) The relative length and intensity of Vista Green-stained DNA tails to heads (measured as olive tail moment, values 
indicated at the top) in each group. Individual olive tail moment of all cells in each group is plotted and presented as mean±
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Belinostat and cisplatin co-treatment induced TRAIP expression and p-IĸB suppression in p53R158G cells.
(A-B) Immunoblotting was performed to evaluate the effects of belinostat/cisplatin on the indicated targets in various p53 
clones 48 hours post-treatment (A). β-actin shown as loading control. Densitometric quantification of TRAIP blots (B), 
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Supplementary Figure 11:
ChIP-qPCR validation of mutp53 binding at TRAIP gene.
(A) Schematic presentation of amplicon locations for qPCR validation of ChIP-Seq target gene. Primers (TRAIP-3’ and 
TRAIP-5’) flanking promoter region of TRAIP gene.
(B-C) qPCR showing p53 (p53wt, p53R158G, p53R158G(K20A)) or IgG enrichment over TRAIP promoter region in Calu-1 cells. 
Primers were designed to enrich the 3’ (B) or 5’ (C) regions of the promoter. Signals obtained from the ChIP are compared 
against the input chromatin amount (ChIP/Input), and presented as mean ± SEM (n = 3 independent experiments). Two 
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p53 status is a key determinant of NFĸB signaling in HCT116 cells when treated with belinostat/cisplatin.
(A-B) Immunofluorescence staining was performed to determine the localization of p65 (Alexa Fluor-488) in HCT116 (p53-
/- and p53wt/wt) cells in vehicle- or drug-treated cells 48 hours post-treatment. At least five independent fields were taken for 
each condition with a minimum of 50 nuclei per group. Representative confocal images are shown at 63x magnification (A). 
Scale bar, 10 µm. Merged images are displayed with blue indicates DAPI, green indicates p65. Integrated density 
quantifying nuclear NFĸB (p65) upon treatment in both HCT116 cells (B). Data are presented as mean ± SD (n = 2 
independent experiments). 
(C-D) Distribution of p65 (in cytoplasm or nucleus) was determined by Western blot (C) after nuclear-cytosolic 
fractionation. TATA-box binding protein (TBP) (nuclear) and α-tubulin (cytoplasmic) were used as loading controls. 
Nuclear p65 signal was quantified with densitometry after normalizing to TBP (D). Data are presented as mean ± SD (n = 3 
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Supplementary Figure 13:
TRAIP activation is observed in codon 158 mutp53 cells and is critical for the induction of apoptosis.
(A-B) Western blot comparing expressions of the indicated targets among H2170 (R158G), H441 (R158L), H661 (R158L), 
H1417 (R175L), H1975 (R273H), HCC70 (R248Q), MDA-MB-468 (R273H) and SK-BR-3 (R175H) in response to 48 
hours vehicle or drug treatment (A). β-actin shown as loading control. Densitometric quantification of TRAIP blots (B), 
normalized to β-actin, is tabulated + SEM (n = 3 independent experiment).
(C) RT-qPCR quantification of TRAIP gene in H2170 cells 48 hours after vehicle or drug treatment. Data are presented as 
average relative quantification ± SD (n = 3 independent experiemnt). Two tailed Student’s t-test; *P < 0.05. 
(D) Western blot evaluating effects of TRAIP knockdown upon treatment in H2170 cells (n = 3 independent experiments). 
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Forced suppression of NFĸB signaling with dominant negative IĸB expression enhances cytotoxicity in both wtp53 
and p53R158G cells.
(A) Western blot showing effects of dominant negative IĸB (pCMV-IĸB(∆N), pCMV-IĸB(S32A)) on the indicated proteins 
in Calu-1 (p53-/-, p53wt, p53R158G) cells 48 hours after vehicle or drug treatment (n = 3 independent experiments). β-actin 
shown as loading control. 
(B) Quantification of apoptotic cell population with Annexin V staining in vector control or IĸB-overexpressed cells 48 
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Supplementary Figure 15: 
Compounds demonstrating selectivity towards p53R158G cells are mostly potent acetylating agent of mutp53. 
(A-B) Downstream effects of selected compounds (agents with higher sensitivity towards p53R158G cells, identified in Figure 
2A) were evaluated in Calu-1 isogenic clones after 48 hours treatment. Western blots comparing regulation of the indicated 
proteins in p53R158G (A) and p53wt (B) cells. β-actin shown as loading control (n = 3 independent experiments).
(C-E) RT-qPCR quantification of MDM2 (C), CDKN1A (D) and TRAIP (E) genes in p53R158G and p53wt cells 48 hours after 
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Supplementary Figure 16: 
Cisplatin, topotecan and JQ1 selectively reduce growth of mutp53R158G tumors.
(A-D) Growth curve analysis of Calu-1 p53wt (A), p53-/- (B), p53R158G (C) and p53R158G(k20A) (D) in xenografts treated with 
vehicle or cisplatin (CDDP; 4 mg/kg). Tumor sizes are presented as mean ± SEM. Two-way ANOVA with Bonferroni 
correction; *P < 0.05; **P < 0.01; ***P < 0.001.
(E) Western blots demonstrating changes of the indicated proteins in tumors of respective treatment (n = 3 independent 
tumours). β-actin shown as loading control. Densitometric quantification of TRAIP expression was tabulated on the right. 
Relative fold change is normalized to β-actin, relative to vehicle control tumors and presented at mean ± SEM. Two tailed 
Student’s t-test; *P < 0.05.
(F-G) Immunohistochemistry staining analyses of intracellular expressions of p65 and Ki67 in respective tumors. 
Representative images at 20× showing p65 staining (F) and Ki67 staining (G). Scale bar, 50 µm. Quantification of 
positively-stained cells (%) in p53wt and p53R158G respectively was tabulated on the right. Data are represented as percentage 
of positive cells ± SD (n = 5 independent tumours). Two tailed Student’s t-test; for xenograft models, *P < 0.05, **P < 
0.01.
(H) RNA in situ hybridisation (RNAscope) showing TRAIP expression in respective tumors. Representative images showing 
TRAIP mRNA signal. Semi-quantitative scoring (0-4) of TRAIP mRNA signal (dots/cell) in p53wt and p53R158G respectively 
was tabulated on the right. Data are represented as scattered dot plot ± SD (n = 5 independent tumours). Scale bar, 50 µm. 
Two tailed Student’s t-test; for xenograft models, **P < 0.01.
(I-K) Growth curve analysis of Calu-1 p53wt (I), p53-/- (J) and p53R158G (K) in xenografts treated with vehicle, JQ1 (30 
mg/kg) or topotecan (1 mg/kg). Tumor sizes are presented as mean ± SEM. Two-way ANOVA with Bonferroni correction; 
*P < 0.05; **P < 0.01; ***P < 0.001.
Disease Total samples
Total Number of 
Sample with 
Mutated TP53




of sample with 
R158 mutation 
(%)
Lung Squamous Cell Carcinoma 178 146 8 4.49
Uterine Corpus Endometrial 
Carcinoma
33 10 1 3.03
Lung adenocarcinoma 564 295 8 1.42
Esophageal carcinoma 186 153 2 1.08
Liver Hepatocellular carcinoma 199 63 2 1.01
Bladder urothelial carcinoma 131 64 1 0.76
Head and Neck squamous cell 
carcinoma
280 205 2 0.71
Stomach Adenocarcinoma 290 138 2 0.69
Glioblastoma multiforme 577 230 3 0.52
Sarcoma 248 85 1 0.40
Breast invasive carcinoma 994 309 1 0.10
Supplementary Table 1
Supplementary Table 1: 
Prevalence and distribution of TP53 codon 158 mutation in various carcinomas according to The Cancer Genome Atlas 




LUAD cases with TP53 Mut
(N = 295 out of 564)
LSCC cases with TP53 Mut 
(N = 146 out of 178)
Lung carcinomas with TP53
Mut (N = 2397 out of 6793)
Non-lung carcinomas with TP53
Mut (N = 1956 out of 6051)
Total # % cases Total # % cases Total # % cases Total # % cases
158 8 2.71 8 5.48 31 1.29 15 0.77
175 3 1.02 3 2.05 97 4.05 91 4.65
245 8 2.71 5 3.42 54 2.25 41 2.10
248 5 1.69 4 2.74 126 5.26 117 5.98
249 10 3.39 3 2.05 31 1.29 18 0.92
273 9 3.05 6 4.11 123 5.13 108 5.52
282 3 1.02 2 1.37 41 1.71 36 1.84
Supplementary Table 2: 
Distribution of various TP53 hotspot mutations (codon 158, 175, 245, 248, 249, 273, 282) in lung adenocarcinoma (LUAD) 
and lung squamous cell carcinoma (LUSC) according to The Cancer Genome Atlas (TCGA) database. Prevalent cases were 
highlighted in red.
Compound
p53R158G p53-/- p53wt p53R158G p53-/- p53wt
Target Compound
p53R158G p53-/- p53wt p53R158G p53-/- p53wt
Target
0.1 µM 1 µM 0.1 µM 1 µM
AC:Docetaxel (Taxotere) 59.5 57.3 42.2 74.9 68.4 44.5
Microtubule 
Associated
AC:Tipifarnib (Zarnestra) 26.1 34.4 9.6 55.0 66.8 53.5
Farnesyltransferase, 
Ras
AC:Torin 2 38.9 47.8 24.1 64.3 61.9 41.2 mTOR AC:PU-H71 18.6 39.6 7.9 61.0 56.8 20.8 HSP
AC:Simvastatin (Zocor) 0.0 10.1 15.4 64.6 71.8 52.3
AC:Entinostat (MS-275, SNDX-
275)
29.1 23.2 3.4 56.8 28.8 51.8 HDAC
AC:Romidepsin (FK228, 
Depsipeptide)
91.3 93.5 89.8 94.6 95.1 93.4 HDAC AC:Dasatinib (BMS-354825) 1.4 6.2 0.0 26.4 54.6 30.4 Src, Bcr-Abl, c-Kit
AC:MLN2238 45.9 73.6 52.9 92.1 93.8 90.7 Proteasome AC:4SC-202 16.4 4.4 16.9 47.2 54.7 23.8 HDAC
AC:Paclitaxel (Taxol) 44.5 59.0 38.5 71.9 64.5 48.5
Microtubule 
Associated
AC:BI6727 (Volasertib) 51.7 14.3 32.6 58.5 43.1 20.8 PLK
AC:Flavopiridol (Alvocidib) 26.7 25.6 29.8 73.8 88.6 60.3 CDK AC:JNK Inhibitor IX 0.0 5.0 7.2 57.6 58.2 30.8 JNK
AC:Epothilone A 73.7 72.1 55.1 79.4 75.1 47.4
Microtubule 
Associated
AC:Picropodophyllin (PPP) 10.5 0.8 6.4 40.9 54.1 17.7 IGF-1R
AC:GSK2126458 1.3 0.0 11.2 28.6 54.5 43.4 PI3K, mTOR AC:Plinabulin (NPI-2358) 39.6 31.7 7.6 73.1 69.8 41.3 VDA
AC:AZD7762 8.7 0.0 0.0 69.6 45.3 44.7 Chk AC:Bleomycin sulfate 34.9 21.4 6.9 59.5 43.7 10.7 DNA/RNA Synthesis
AC:Nocodazole 0.0 10.6 6.5 55.3 46.3 39.2
Microtubule 
Associated
AC:Vincristine 59.5 63.7 28.1 79.2 80.6 35.8
Autophagy,Microtu
bule
AC:MLN9708 29.8 49.9 35.5 91.6 94.4 92.1 Proteasome AC:Voreloxin (SNS-595) 48.2 38.4 7.3 58.2 60.2 39.1 Topoisomerase
AC:GSK923295 21.2 56.5 23.9 42.1 64.2 39.9 Kinesin AC:Mitoxantrone HCl 35.2 12.8 0.0 66.5 65.3 67.6
AC:Bortezomib (Velcade) 85.7 92.0 89.0 93.9 93.7 91.2 Proteasome AC:LY3009120 23.8 9.1 9.8 50.7 70.3 21.7 Raf
AC:Elesclomol 75.6 94.6 66.9 94.4 94.6 93.8 HSP AC:MK-1775 3.1 0.0 0.0 52.1 50.5 11.4 Wee1
AC:Topotecan HCl 43.7 26.3 11.8 58.3 21.8 15.9 Topoisomerase AC:PIK-75 45.8 65.8 0.0 78.2 92.4 62.3 PI3K, DNA-PK
AC:Floxuridine (Fludara) 37.2 21.4 18.7 68.0 50.5 24.3 DNA/RNA Synthesis AC:Teniposide (Vumon) 43.9 11.2 0.0 69.6 55.1 11.9
AC:Gemcitabine (Gemzar) 53.5 65.9 38.3 61.0 64.8 44.9 AC:Clofarabine 13.3 0.0 0.0 59.5 57.9 35.4 DNA/RNA Synthesis
AC:GSK461364 42.8 42.9 49.8 65.8 54.3 43.4 PLK SkEpi:JIB-04 0.0 9.3 15.9 67.3 62.7 87.8
Histone 
Demethylase
AC:PF-3758309 11.0 49.4 17.8 42.1 61.6 26.7 PAK SkEpi:TAK-901 13.2 24.6 25.1 36.4 50.0 60.0 Aurora Kinase
AC:KX2-391 36.8 64.5 27.8 69.5 76.0 38.5 Src SkEpi:LAQ824 (Dacinostat) 63.3 61.7 48.5 97.9 96.9 95.4 HDAC
AC:Mitoxantrone 34.6 37.7 10.0 71.1 70.0 73.3 Topoisomerase SkEpi:M344 6.8 14.3 21.4 45.0 31.6 31.0 HDAC
AC:Bexarotene 37.5 53.7 41.1 35.1 46.7 19.8 SkEpi:(+)-JQ1 15.3 21.3 25.5 54.7 42.1 35.8
Epigenetic Reader 
Domain
AC:CYT997 (Lexibulin) 40.7 41.8 28.2 78.1 81.2 43.5
Microtubule 
Associated
SkEpi:ENMD-2076 17.7 11.7 23.3 33.0 46.1 41.5
Aurora 
Kinase,FLT3,VEGFR
AC:HSP990 (NVP-HSP990) 64.1 60.6 38.5 83.5 80.9 48.3 HSP SkEpi:4SC-202 0.0 7.9 17.1 68.9 61.5 60.8 HDAC
AC:Cladribine 0.0 16.6 0.0 51.5 38.3 25.9 DNA/RNA Synthesis SkEpi:Pracinostat (SB939) 0.0 0.4 17.2 49.2 56.7 49.9 HDAC
AC:SB939 (Pracinostat) 19.4 0.1 13.4 51.7 34.7 55.7 HDAC SkEpi:TG101209 6.6 11.4 23.8 31.8 44.2 29.4 JAK,FLT3,c-RET
AC:Triptolide 65.5 86.5 42.6 81.4 91.8 67.1 SkEpi:Hesperadin 14.4 25.2 46.6 62.2 70.6 70.2 Aurora Kinase
AC:Ganetespib (STA-9090) 77.5 70.8 34.4 78.4 73.6 45.2 HSP SkEpi:Trichostatin A (TSA) 16.4 24.8 32.1 97.5 94.0 89.1 HDAC
AC:BIIB021 11.3 2.6 0.0 70.1 60.1 45.3 HSP SkEpi:FG-4592 0.0 12.5 19.8 22.2 6.4 45.5 HIF
AC:Trichostatin A (TSA) 11.9 0.0 1.4 87.9 83.3 55.3 HDAC
SkEpi:Quisinostat (JNJ-
26481585)
94.5 86.3 81.2 98.3 98.2 98.1 HDAC
AC:AUY922 (NVP-AUY922) 77.5 74.0 29.3 77.9 72.3 43.4 HSP
SkEpi:Romidepsin (FK228, 
Depsipeptide)
98.6 98.6 98.4 98.9 99.0 98.8 HDAC
AC:BI 2536 62.8 54.6 33.6 58.6 39.0 18.0 PLK SkEpi:CX-6258 HCl 27.9 25.1 21.1 52.7 41.9 41.3 Pim
AC:Flavopiridol (Alvocidib) HCl 0.0 7.1 0.0 68.1 86.9 57.5 CDK SkEpi:CUDC-907 96.0 93.0 80.5 98.5 98.3 98.0 PI3K,HDAC
AC:Disulfiram (Antabuse) 0.0 0.0 0.0 41.3 70.9 55.6 SkEpi:Alisertib (MLN8237) 40.8 29.5 39.0 37.8 31.2 28.3 Aurora Kinase
AC:Bosutinib (SKI-606) 16.9 0.0 4.8 52.7 49.8 13.9 Src SkEpi:Entinostat (MS-275) 0.0 11.5 10.9 28.2 32.7 44.4 HDAC
AC:GW3965 HCl 44.7 20.9 45.9 62.9 59.0 67.5 Liver X Receptor SkEpi:AZ 960 5.5 19.7 21.6 71.5 71.4 64.7 JAK
AC:Deltarasin 0.0 13.0 8.9 22.7 50.6 47.2 PDE SkEpi:Belinostat (PXD101) 22.6 0.0 12.8 55.9 41.6 39.6 HDAC
AC:Ro3280 48.9 21.6 30.3 65.7 55.4 38.3 PLK
SkEpi:Mocetinostat 
(MGCD0103)
18.1 5.8 13.9 40.8 40.8 42.1 HDAC
AC:Vinorelbine Tartrate 59.6 58.9 37.0 71.5 77.0 32.0
Microtubule 
Associated
SkEpi:Azacitidine 0.0 20.2 24.1 37.0 52.6 46.1
DNA 
Methyltransferase
AC:PFK15 5.8 4.5 10.0 19.8 72.6 8.1 SkEpi:Aurora A Inhibitor I 18.3 16.3 28.2 23.4 41.8 44.2 Aurora Kinase
AC:VER-50589 37.5 9.4 0.0 82.9 73.5 29.9 HSP SkEpi:Givinostat (ITF2357) 0.0 4.0 21.4 55.9 69.1 50.6 HDAC
AC:17-AAG (Tanespimycin) 0.0 5.8 0.0 56.2 48.2 0.0 HSP SkEpi:Panobinostat (LBH589) 91.1 85.6 69.9 98.5 98.3 97.6 HDAC
AC:17-DMAG HCl
(Alvespimycin)
78.6 68.7 21.8 77.0 68.2 31.4 HSP SkEpi:TG101348 (SAR302503) 0.0 14.0 13.8 35.3 44.0 26.6 JAK
AC:SNS-032 (BMS-387032) 12.1 6.5 0.0 39.6 57.6 44.7 CDK SkEpi:MK-5108 (VX-689) 0.0 4.6 14.7 54.6 40.9 48.8 Aurora Kinase
AC:Pexmetinib (ARRY-614) 12.1 14.7 0.0 73.6 77.7 39.7 p38 MAPK SkEpi:CUDC-101 26.0 12.7 30.9 54.7 34.3 65.1 EGFR,HER2,HDAC
AC:INK 128 (MLN0128) 3.0 14.4 0.0 45.7 61.6 29.8 mTOR SkEpi:PCI-24781 (Abexinostat) 8.4 3.9 23.3 54.5 63.5 53.3 HDAC
AC:CH5138303 16.8 0.0 12.8 76.1 57.8 27.8 HSP EzEpi:Trichostatin A 24.3 20.9 30.6 97.9 95.3 90.8 HDAC
AC:Rigosertib (ON-01910) 43.0 40.7 1.1 79.2 68.9 38.7 PLK EzEpi:Oxamflatin 26.4 0.7 21.8 55.9 29.9 43.2 HDAC
AC:Epothilone B (EPO906) 70.2 68.6 46.8 74.1 72.0 52.0
Microtubule 
Associated
AC:CB-839 74.4 82.9 75.7 88.6 93.1 85.6
AC:Pelitinib (EKB-569) 6.1 31.8 1.9 46.8 71.7 20.1 EGFR
AC:MI-2 (MALT1 inhibitor) 35.3 34.2 31.1 94.8 95.8 94.1
AC:Obatoclax mesylate (GX15-
070)
0.0 0.0 0.0 68.7 65.9 38.2 Bcl-2
0.0 20.0 40.0 60.0 80.0 100.0
AC:BI-847325 9.3 21.3 0.0 31.6 60.8 33.6 MEK
AC:JNJ-26481585 54.3 44.9 24.7 93.7 93.9 85.2 HDAC % of growth inhibition
AC:Ispinesib (SB-715992) 57.6 62.6 47.2 66.2 69.8 58.0 Kinesin
AC:ARQ 621 26.6 10.0 16.4 55.9 66.7 60.1 Kinesin
Supplementary Table 3
Supplementary Table 3: 
Inhibition scores of anti-cancer agents and epigenetic modulators against Calu-1 isogenic cells (p53-/-, p53wt, p53R158G) at 0.1 
and 1 µM of respective inhibitors.
Genes
fold change (log2) ChIP-seq
p53R158G U p53R158G T p53wt T p53R158G T
p53wt p53R158G
p53wt U p53wt T p53wt U p53R158G U
PCNA -0.961 0.404 1.636 3.001 X X
POLA2 -0.949 0.192 1.614 2.756 X
RFC4 -0.704 0.499 1.554 2.756 X X
RAD51 -0.87 -0.078 1.976 2.767 X
TRAIP -1.075 0.646 1 2.72 X
USP1 -0.131 0.064 1.599 1.794 X X
POLE3 -0.168 0.08 1.504 1.752 X
PSME3 0.06 -0.346 1.984 1.578 X
CDK1 -0.302 0.423 0.938 1.662 X
ANAPC7 -0.391 0.23 1.128 1.749 X
PSMC4 -0.953 -0.351 1.355 1.957 X
CDC7 -0.431 -0.854 2.537 2.114 X X
CYCS -0.833 -1.114 2.425 2.144 X
CHEK1 -1.379 -1.392 1.505 1.492 X X
TJP2 -0.919 0.638 0.526 2.082 X X
RBL1 -0.95 0.6 0.478 2.029 X X
MSH2 -1.033 0.734 -0.074 1.693 X
POLE3 -0.08 1.253 0.183 1.516 X
EXO1 -2.142 0.745 1.914 4.801 X X
ORC1 -1.964 0.318 1.411 3.693 X
PMAIP1 -1.336 -2.121 2.44 1.655 X
CDKN1A -2.17 -2.701 2.131 1.601 X
TNFRSF10B 2.006 -0.657 2.606 -0.057 X
RPS27L 1.633 -1.123 1.878 -0.878 X
MDM2 -0.258 -1.769 2.275 0.764 X
GADD45A 0.352 -1.48 1.814 -0.018 X
TDG 1.392 0.253 2.543 1.404 X X
ATF3 2.586 -1.578 4.887 0.723 X X
Supplementary Table 4
Supplementary Table 4: 
Transcriptomic regulation (in fold changes) of wtp53 and p53R158G pre- and post- treatment (presented as the fold change 
of belinostat/cisplatin combination), as well as the respective p53 binding to TSS. Blue indicates ChIP binding of p53wt; red 
indicates ChIP binding of p53R148G.
-3 -1 0 1 3 5
fold change (log2)
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Supplementary Table 5: 
Sequences for primers and probes used for RT-qPCR and ChIP-qPCR.
